Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson, Gabriela Plesa, Fang Chen, Megan M Davis, Wei-Ting Hwang, Regina M Young, Jennifer L Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L Siegel, Bruce L Levine, Carl H June, Michael C Milone. J Clin Invest 2019
Times Cited: 304
Times Cited: 304
Zhiling Yan, Jiang Cao, Hai Cheng, Jianlin Qiao, Huanxin Zhang, Ying Wang, Ming Shi, Jianping Lan, Xiaoming Fei, Lai Jin, Guangjun Jing, Wei Sang, Feng Zhu, Wei Chen, Qingyun Wu, Yao Yao, Gang Wang, Jing Zhao, Junnian Zheng, Zhenyu Li, Kailin Xu. Lancet Haematol 2019
Times Cited: 136
Times Cited: 136
List of shared articles
Times cited
Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Arjun Lakshman, Shaji K Kumar. Am J Hematol 2022
Arjun Lakshman, Shaji K Kumar. Am J Hematol 2022
Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.
Yang Liu, Wei Chen, Mingxiao Yu, Hujun Li, Hai Cheng, Jiang Cao, Zhiling Yan, Ming Shi, Feng Zhu, Haiying Sun,[...]. Transplant Cell Ther 2022
Yang Liu, Wei Chen, Mingxiao Yu, Hujun Li, Hai Cheng, Jiang Cao, Zhiling Yan, Ming Shi, Feng Zhu, Haiying Sun,[...]. Transplant Cell Ther 2022
Resistance and recurrence of malignancies after CAR-T cell therapy.
Wanying Zeng, Pumin Zhang. Exp Cell Res 2022
Wanying Zeng, Pumin Zhang. Exp Cell Res 2022
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso, Juan-José Lahuerta. Biomark Res 2022
José-Ángel Hernández-Rivas, Rafael Ríos-Tamayo, Cristina Encinas, Rafael Alonso, Juan-José Lahuerta. Biomark Res 2022
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Wenjing Luo, Chenggong Li, Yinqiang Zhang, Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu. BMC Cancer 2022
Wenjing Luo, Chenggong Li, Yinqiang Zhang, Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu. BMC Cancer 2022
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.
Huan Zhang, Man Liu, Xia Xiao, Hairong Lv, Yanyu Jiang, Xin Li, Ting Yuan, Mingfeng Zhao. Leuk Lymphoma 2022
Huan Zhang, Man Liu, Xia Xiao, Hairong Lv, Yanyu Jiang, Xin Li, Ting Yuan, Mingfeng Zhao. Leuk Lymphoma 2022
Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.
Raphaëlle Toledano Zur, Galit Adler, Katerina Shamalov, Yair Tal, Chen Ankri, Cyrille J Cohen. Exp Suppl 2022
Raphaëlle Toledano Zur, Galit Adler, Katerina Shamalov, Yair Tal, Chen Ankri, Cyrille J Cohen. Exp Suppl 2022
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Ying Wang, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu,[...]. J Clin Oncol 2022
Ying Wang, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu,[...]. J Clin Oncol 2022
CAR T cell therapy for multiple myeloma: What have we learned?
Sandra Susanibar Adaniya, Edward A Stadtmauer, Adam D Cohen. Leukemia 2022
Sandra Susanibar Adaniya, Edward A Stadtmauer, Adam D Cohen. Leukemia 2022
Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials.
Jingjing Li, Yuanyan Tang, Zhiping Huang. Transl Cancer Res 2022
Jingjing Li, Yuanyan Tang, Zhiping Huang. Transl Cancer Res 2022
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Barry Paul, Cesar Rodriguez, Saad Z Usmani. Drugs 2022
Barry Paul, Cesar Rodriguez, Saad Z Usmani. Drugs 2022
Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
Xue Wang, Lina Zhao, Jing Wang, Yue Yao, Jiaojiao Wang, Shengwei Ji, Tian Hua, Shiyuan Wang, Hai Cheng, Ming Shi,[...]. Front Immunol 2022
Xue Wang, Lina Zhao, Jing Wang, Yue Yao, Jiaojiao Wang, Shengwei Ji, Tian Hua, Shiyuan Wang, Hai Cheng, Ming Shi,[...]. Front Immunol 2022
Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.
Rajat Bansal, Ran Reshef. Blood Rev 2021
Rajat Bansal, Ran Reshef. Blood Rev 2021
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Binod Dhakal, Parameswaran N Hari, Saad Z Usmani, Mehdi Hamadani. Bone Marrow Transplant 2021
Binod Dhakal, Parameswaran N Hari, Saad Z Usmani, Mehdi Hamadani. Bone Marrow Transplant 2021
CAR T cell therapies for patients with multiple myeloma.
Lekha Mikkilineni, James N Kochenderfer. Nat Rev Clin Oncol 2021
Lekha Mikkilineni, James N Kochenderfer. Nat Rev Clin Oncol 2021
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Norihiro Watanabe, Mary Kathryn McKenna, Amanda Rosewell Shaw, Masataka Suzuki. Mol Ther 2021
Norihiro Watanabe, Mary Kathryn McKenna, Amanda Rosewell Shaw, Masataka Suzuki. Mol Ther 2021
Conventional T cell therapies pave the way for novel Treg therapeutics.
Lucy Z Li, Zheng Zhang, Vijay G Bhoj. Cell Immunol 2021
Lucy Z Li, Zheng Zhang, Vijay G Bhoj. Cell Immunol 2021
Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao,[...]. Cancer Med 2021
Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao,[...]. Cancer Med 2021
Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients.
Ghulam Rehman Mohyuddin, Anthony Rooney, Nicole Balmaceda, Muhammad Aziz, Douglas W Sborov, Brian McClune, Shaji K Kumar. Blood Adv 2021
Ghulam Rehman Mohyuddin, Anthony Rooney, Nicole Balmaceda, Muhammad Aziz, Douglas W Sborov, Brian McClune, Shaji K Kumar. Blood Adv 2021
Immunogenicity of CAR T cells in cancer therapy.
Dimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher, Nabil Ahmed, Mohamad Hamieh, Meenakshi Hegde, Marco Ruella, Barbara Savoldo, Nirali N Shah, Cameron J Turtle,[...]. Nat Rev Clin Oncol 2021
Dimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher, Nabil Ahmed, Mohamad Hamieh, Meenakshi Hegde, Marco Ruella, Barbara Savoldo, Nirali N Shah, Cameron J Turtle,[...]. Nat Rev Clin Oncol 2021
Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study.
Hongyuan Dai, Shuya Xu, Jing Han, Zhenyu Li, Jiang Cao, Tingyu Hu, Hongxia Li, Jing Wei, Xue Dou, Fang Zhou,[...]. J Affect Disord 2021
Hongyuan Dai, Shuya Xu, Jing Han, Zhenyu Li, Jiang Cao, Tingyu Hu, Hongxia Li, Jing Wei, Xue Dou, Fang Zhou,[...]. J Affect Disord 2021
Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Qin Yang, Xin Li, Fangrong Zhang, Qiaohui Yang, Wen Zhou, Jing Liu. Int J Med Sci 2021
Qin Yang, Xin Li, Fangrong Zhang, Qiaohui Yang, Wen Zhou, Jing Liu. Int J Med Sci 2021
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Faroogh Marofi, Safa Tahmasebi, Heshu Sulaiman Rahman, Denis Kaigorodov, Alexander Markov, Alexei Valerievich Yumashev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Rebar N Mohammed,[...]. Stem Cell Res Ther 2021
Faroogh Marofi, Safa Tahmasebi, Heshu Sulaiman Rahman, Denis Kaigorodov, Alexander Markov, Alexei Valerievich Yumashev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Rebar N Mohammed,[...]. Stem Cell Res Ther 2021